Should investors expect more EPS surprises from GILD in 2025?

**Gilead Sciences (GILD) is poised for a potential EPS surprise in 2025**, considering the following factors:

1. **Consistent Positive Performance**: GILD has a track record of positive EPS surprises, having not missed the consensus estimate in any of the last four quarters. This consistency suggests a strong operational efficiency and a reliable growth trajectory.
2. **Earnings Growth Projections**: The company's earnings per share (EPS) are expected to increase significantly, with a projected 70.13% change in 2025 compared to the previous year. This substantial growth is underpinned by a robust rebound in EPS, which is expected to reach $7.87 per share in 2025, reflecting a 69.91% change from the previous year.

3. **Analyst Confidence**: Analyst sentiment is positive, with recent revisions in estimates reflecting confidence in GILD's business performance and profit potential. The Zacks Rank, which GILD currently holds, is a functional rating system that integrates estimate changes and has an impressive track record of outperformance.
4. **Industry Outperformance**: GILD has outperformed its Medical peers in terms of year-to-date performance, with a return of 16.8% compared to the Medical sector's 3.6% gain. This sector outperformance can translate into stronger EPS growth as the company continues to excel relative to industry averages.
5. **Strategic Positioning**: GILD's strategic acquisitions and focus on innovative therapies position it well for sustained growth. The company's extensive portfolio and leadership in treating HIV and liver diseases are key factors in its favor.

In conclusion, investors can expect more EPS surprises from GILD in 2025 due to the company's strong financial performance, positive analyst sentiment, and strategic positioning in the pharmaceutical sector.